Nephropathy Clinical Trials in Houston, Texas
17 recruitingHouston, Texas
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 2
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 2
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.30 enrolled40 locationsNCT07157787
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 1
Study of BHV-1400 in IgA Nephropathy
IgA Nephropathy
Biohaven Therapeutics Ltd.20 enrolled12 locationsNCT07054684
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.96 enrolled16 locationsNCT06557265
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Blood PressureNeuropathyDiabetes+6 more
Jaeb Center for Health Research200 enrolled18 locationsNCT06837181
Recruiting
Phase 4
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
IgA Nephropathy
Calliditas Therapeutics AB60 enrolled38 locationsNCT06712407
Recruiting
Phase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Nephrotic Syndrome Study Network
Membranous NephropathyGlomerulosclerosis, Focal SegmentalMinimal Change Disease (MCD)
University of Michigan1,200 enrolled44 locationsNCT01209000
Recruiting
Phase 2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
IgA Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.25 enrolled5 locationsNCT06740526
Recruiting
Phase 3
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Primary Membranous Nephropathy
Cerium Pharmaceuticals, Inc.148 enrolled31 locationsNCT05696613